Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RAIN

Rain Oncology (RAIN) Stock Price, News & Analysis

Rain Oncology logo

About Rain Oncology Stock (NASDAQ:RAIN)

Advanced Chart

Key Stats

Today's Range
$4.91
$7.25
50-Day Range
$1.20
$1.24
52-Week Range
$0.82
$11.32
Volume
60,579 shs
Average Volume
32,376 shs
Market Capitalization
$37.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

As of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Stock News Headlines

What is Warren Buffett Hiding?
Warren Buffett just poured $40 billion into one quiet sector—and now investors are calling this dividend play the “last retirement stock you’ll ever need.” It’s not a tech company or AI darling. But it’s raking in cash and paying a nearly 8% dividend—even as the broader market stumbles.
See More Headlines

RAIN Stock Analysis - Frequently Asked Questions

Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.20) earnings per share for the quarter.

Rain Oncology (RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional shareholders of Rain Oncology include Polar Asset Management Partners Inc. (0.52%) and Apollo Management Holdings L.P. (0.43%). Insiders that own company stock include Bvf Partners L P/Il, Boxer Capital, Llc, Franklin M Berger and Paul T Dacier.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and

Company Calendar

Last Earnings
5/15/2025
Today
5/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
63
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$3.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.92 per share
Price / Cash Flow
7.41
Book Value
($0.69) per share
Price / Book
-9.90

Miscellaneous

Free Float
4,574,000
Market Cap
$37.84 million
Optionable
No Data
Beta
-0.11
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:RAIN) was last updated on 5/18/2025 by MarketBeat.com Staff
From Our Partners